Company
Headquarters: Taipei City, Taiwan
Employees: 35
TW$8.56 Billion
TWD as of July 1, 2025
US$292.3 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
CHO Pharma, Inc., a biopharmaceutical company, develops and commercializes therapeutic and diagnostic products for the unmet clinical needs. It is developing homogeneous antibody drugs, such as CHO-H01, CHO-H02, and CHO-A04 for cancer; CHO-H03, a homogeneous antibody drug for autoimmune diseases; CHO-S05 dual-effect anti-flu drugs; and CHO-V07 glycan-based vaccines and drugs. The company was founded in 2013 and is based in Taipei City, Taiwan.
CHO Pharma, Inc. has the following listings and related stock indices.
Stock: TWSE: 6586 wb_incandescent